|Min SIP Amount||₹100|
|NAV||₹145.4 (23 Aug 2019)|
|Fund Started||01 Jan 2013|
|Fund Size||₹2,344 Cr|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||11.8%|
|Divi's Laboratories Ltd.||Healthcare||Equity||10.4%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||8.0%|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||6.6%|
|Syngene International Ltd.||Healthcare||Equity||6.5%|
|Abbott India Ltd.||Healthcare||Equity||6.3%|
|Sanofi India Ltd.||Healthcare||Equity||5.9%|
|Fortis Healthcare (India) Ltd||Healthcare||Equity||5.8%|
Reliance Pharma Fund Direct Growth is a Equity Mutual Fund Scheme launched by Reliance Mutual Fund. This scheme was introduced to investors on 01 Jan 2013. Sailesh Raj Bhan is the Current Fund Manager of Reliance Pharma Fund Direct Growth.The fund currently has an Asset Under Management(AUM) of ₹2,344 Cr and the Latest NAV as of 23 Aug 2019 is ₹145.4.
The Reliance Pharma Fund Direct Growth is rated High risk. Minimum SIP Investment is 100. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 year.
1st Floor, Proms Complex, SBI
Colony, 1A Koramangala, 560034